These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11908770)

  • 1. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
    Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
    Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
    Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
    Crespi CL; Miller VP
    Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
    Stearns RA; Chakravarty PK; Chen R; Chiu SH
    Drug Metab Dispos; 1995 Feb; 23(2):207-15. PubMed ID: 7736913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
    Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
    Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.